Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932962 | 1.00 | CA1 (0.45) | CA1CA2CA7CA9TMEM97 | |
| SCHEMBL565818 | 0.86 | TMEM97 (0.48) | CA2TMEM97SIGMAR1TSHR | |
| SCHEMBL2182755 | 0.86 | TMEM97 (0.48) | CA2TMEM97SIGMAR1TSHR | |
| SCHEMBL5606199 | 0.86 | TMEM97 (0.48) | CA2TMEM97SIGMAR1TSHR | |
| SCHEMBL29342924 | 0.85 | TMEM97 (0.40) | CA1CA2CA7CA9TMEM97 | |
| SCHEMBL29342981 | 0.83 | TMEM97 (0.39) | CA1CA2CA7CA9TMEM97 | |
| SCHEMBL10905872 | 0.83 | CA2 (0.49) | CA2TMEM97SIGMAR1MAPK1TSHR | |
| SCHEMBL9170923 | 0.83 | TMEM97 (0.41) | TMEM97SIGMAR1TSHRKDM4EMEN1 | |
| SCHEMBL29342889 | 0.82 | TMEM97 (0.35) | CA1CA2CA7CA9TMEM97 | |
| SCHEMBL3508958 | 0.82 | TMEM97 (0.45) | CA2TMEM97SIGMAR1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2720999-B1 | NOVEL LIPIDOMIMETIC COMPOUNDS AND USES THEREOF | KONINKLIJKE PHILIPS NV (NL) | 2017-08-23 | — | — | EP | disclosed |
| US-9061062-B2 | Lipidomimetic compounds and uses thereof | KONINKLIJKE PHILIPS N.V. (NL) | 2015-06-23 | — | — | US | disclosed |
| US-9061062-B2 | Lipidomimetic compounds and uses thereof | KONINKLIJKE PHILIPS N.V. (NL) | 2015-06-23 | — | — | US | disclosed |
| US-20140127135-A1 | NOVEL LIPIDOMIMETIC COMPOUNDS AND USES THEREOF | KONINKLIJKE PHILIPS N.V. (NL) | 2014-05-08 | — | — | US | disclosed |
| US-20140127135-A1 | NOVEL LIPIDOMIMETIC COMPOUNDS AND USES THEREOF | KONINKLIJKE PHILIPS N.V. (NL) | 2014-05-08 | — | — | US | disclosed |
| WO-2012172457-A1 | NOVEL LIPIDOMIMETIC COMPOUNDS AND USES THEREOF | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-12-20 | — | — | WO | disclosed |
| EP-2535326-A1 | Novel lipidomimetic compounds and uses thereof | Koninklijke Philips Electronics N.V. (NL) | 2012-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127135-A1 | NOVEL LIPIDOMIMETIC COMPOUNDS AND USES THEREOF | SGMS1, SGMS2, LIPA | CA1 1522/4885CA2 978/4885CA7 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.